https://www.selleckchem.com/pr....oducts/alw-ii-41-27.
From a societal perspective, QIVc was more effective and less expensive compared to QIVe, leading to a cost-saving of €3.4 million. From a public payer perspective, the incremental cost-effectiveness ratio for QIVc vs QIVe was €12,852 per QALY gained. In conclusion, QIVc offers a cost-effective alternative to QIVe and should be considered as an alternative vaccine to QIVe for people aged 9-64 at high-risk of influenza complications in Spain.We performed whole-genome sequencing of two phytoplasmas associated with sugarcane grassy sh
Like
Comment
Share
